Skip to content

Not actual patient.

For your HBV patients

HEPATITIS DELTA

adds layers of risk for disease progression1

Hepatitis D is the most severe, potentially underdiagnosed form of chronic viral hepatitis with no FDA-approved treatment.1-3

See burden of disease 

Hepatitis D is the most severe, potentially underdiagnosed form of chronic viral hepatitis with no FDA-approved treatment.1-3

See burden of disease 

Experts recommend screening hep B patients with certain key risk factors4

Experts recommend screening hep B patients with certain key risk factors4

GUIDELINES FOR
TESTING & DIAGNOSIS 

Up to
80%

Up to 80% of chronic hep D patients in the US develop cirrhosis and liver failure within 5‑10 years1

UP TO
80%

of chronic hep D patients in the US develop cirrhosis and liver failure within 5-10 years1

More about
Burden of Disease 

Persons from endemic regions are the largest group at risk of hep delta5

Persons from endemic regions are the largest group at risk of hep delta5

SEE MAP OF
ENDEMIC AREAS 

References: 1. Centers for Disease Control and Prevention. Hepatitis D questions and answers for health professionals. Updated March 9, 2020. Accessed August 9, 2021. https://www.cdc.gov/hepatitis/hdv/hdvfaq.htm 2. World Health Organization. Hepatitis D fact sheet. Updated July 28, 2021. Accessed August 9, 2021. https://www.who.int/news-room/fact-sheets/detail/hepatitis-d 3. Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011–2016. Clin Infect Dis. 2019;69(4):709-712. doi:10.1093/cid/ciz001 4. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. doi:10.1002/hep.29800 5. Toy M, Ahishalı E, Yurdaydın C. Hepatitis delta virus epidemiology in the industrialized world. AIDS Rev. 2020;22:203-212. doi:10.24875/AIDSRev.20000056